Short answer
Gossamer Bio, Inc. (GOSS) filed its Q1 2026 10-Q quarterly report on May 15, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $17M (up 71.5% year over year) with net income of −$47M.
Q1 2026 key financials · XBRL
- Revenue
- $17M
- +71.5% YoY
- Net income
- −$47M
- −27.4% YoY
- Operating margin
- -264.6%
- EPS (diluted)
- −$0.20
- −25.0% YoY
Source: XBRL data from the Gossamer Bio, Inc. (GOSS) Q1 2026 10-Q on SEC EDGAR. USD.
Gossamer Bio, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $17.0M, up $7.1M YoY from Chiesi research and development services
- Net loss $46.7M vs $36.6M YoY; operating loss $44.9M vs $36.8M
- Seralutinib R&D highest program at $42.4M vs $36.3M; terminated programs $0 vs $1.8M
- Cash and securities $99.2M; operating cash use $38.7M vs $39.7M YoY
- FDA dialogue ongoing; NDA submission expected September 2026 despite PROSERA missing alpha threshold; SERANATA enrollment paused
Risk Factors
- No risk-factors section provided in the submitted excerpt
- No newly added risk trigger identifiable from the excerpt
- No updated regulatory, legal, operational, competitive, or financial risk disclosed
- Securities-trading arrangements: no officers or directors adopted or terminated Rule 10b5-1 plans during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gossamer Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.